KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Retained Earnings: 2020-2024

Historic Retained Earnings for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to -$1.4 billion.

  • Recursion Pharmaceuticals' Retained Earnings fell 53.85% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 53.85%. This contributed to the annual value of -$1.4 billion for FY2024, which is 47.92% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Retained Earnings of -$1.4 billion as of FY2024, which was down 47.92% from -$967.6 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Retained Earnings ranged from a high of -$213.6 million in FY2020 and a low of -$1.4 billion during FY2024.
  • Its 3-year average for Retained Earnings is -$1.0 billion, with a median of -$967.6 million in 2023.
  • Data for Recursion Pharmaceuticals' Retained Earnings shows a maximum YoY tumbled of 87.30% (in 2021) over the last 5 years.
  • Recursion Pharmaceuticals' Retained Earnings (Yearly) stood at -$213.6 million in 2020, then slumped by 87.30% to -$400.1 million in 2021, then crashed by 59.86% to -$639.6 million in 2022, then slumped by 51.30% to -$967.6 million in 2023, then crashed by 47.92% to -$1.4 billion in 2024.